- Home
- BOLT vs PIRS Comparison
BOLT vs PIRS Comparison
Compare BOLT & PIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- PIRS
- Stock Information
- Founded
- BOLT 2015
- PIRS 2001
- Country
- BOLT United States
- PIRS United States
- Employees
- BOLT N/A
- PIRS N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- PIRS Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- PIRS Health Care
- Exchange
- BOLT Nasdaq
- PIRS Nasdaq
- Market Cap
- BOLT 25.3M
- PIRS 22.4M
- IPO Year
- BOLT 2021
- PIRS N/A
- Fundamental
- Price
- BOLT $0.57
- PIRS $15.87
- Analyst Decision
- BOLT Hold
- PIRS
- Analyst Count
- BOLT 5
- PIRS 0
- Target Price
- BOLT $1.25
- PIRS N/A
- AVG Volume (30 Days)
- BOLT 126.9K
- PIRS 35.2K
- Earning Date
- BOLT 11-12-2024
- PIRS 11-13-2024
- Dividend Yield
- BOLT N/A
- PIRS N/A
- EPS Growth
- BOLT N/A
- PIRS N/A
- EPS
- BOLT N/A
- PIRS N/A
- Revenue
- BOLT $9,779,000.00
- PIRS $1,352,000.00
- Revenue This Year
- BOLT $16.30
- PIRS N/A
- Revenue Next Year
- BOLT N/A
- PIRS N/A
- P/E Ratio
- BOLT N/A
- PIRS N/A
- Revenue Growth
- BOLT 35.86
- PIRS N/A
- 52 Week Low
- BOLT $0.55
- PIRS $6.20
- 52 Week High
- BOLT $1.56
- PIRS $22.32
- Technical
- Relative Strength Index (RSI)
- BOLT 29.99
- PIRS 38.32
- Support Level
- BOLT $0.63
- PIRS $15.69
- Resistance Level
- BOLT $0.69
- PIRS $16.97
- Average True Range (ATR)
- BOLT 0.03
- PIRS 0.63
- MACD
- BOLT -0.01
- PIRS -0.13
- Stochastic Oscillator
- BOLT 3.49
- PIRS 8.85
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About PIRS Pieris Pharmaceuticals Inc.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.